The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

Physician–scientists at the University of Utah's John A. Moran Eye Center have published an investigatory review of nine patients who experienced vision complications while taking popular semaglutide ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, ...

After repeatedly wowing investors, Roche’s star eye med Vabysmo collected more than $4 billion in sales during its third year ...

Diabetic macular edema remains an important cause of vision loss among patients with diabetes mellitus. Improved control of blood pressure and blood sugar, as well as photocoagulation, are ...

Designed for people experiencing macular degeneration—the leading cause of vision loss among people over the age of 60—the glasses mimic insect eyes, which use anywhere from dozens to ...

The company says that in pre-clinical tests performed on 30 people with macular degeneration, all of the participants experienced a reading speed increase of at least 50% when using the glasses.

Ocugen announced the first patient in its OCU200 phase 1 clinical trial for diabetic macular edema (DME) has been dosed. The company describes OCU200 as a “recombinant fusion protein that consists of ...

today announced that the first patient has been dosed in the OCU200 Phase 1 clinical trial for diabetic macular edema (DME). “OCU200 has the potential to change the treatment landscape for DME ...